Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Nutraceutix(nutx .96) inhibits lung cancer! News story -- Ignore unavailable to you. Want to Upgrade?

To: Moosie who wrote (16)	5/6/1998 7:56:00 PM
From: sean sullivan	Respond to of 57

Letter to shareholders from 3-17-98 Old news, but until recently it was difficult to get any news from the co. Evidently they have hired a PR firm to promote their products and stock. I hope they keep it up; NUTX should have a promising future if they can draw attention to their products. Shareholder Letter March 17, 1998 Dear Shareholder: 1997 stands out as a remarkable year for our company, a year of unprecedented growth, both operationally and financially. Overall, though we expect to book a small loss for the year, we are very pleased with our accomplishments which, considered together, are significant for a company our size. The progress we made was not achieved by accident. We set ambitious goals. We chose the right strategy and executed well. We paid attention to our customers and our competitors alike. And we raised the bar of what we expected of ourselves and each other. Revenues for the year totaled $4.3 million, with the greater percentage of growth occurring towards the end of the year. The increase in revenue was largely attributed to increased private label supplement manufacturing. We are pleased to report that sales momentum has continued to build into 1998 and we anticipate first quarter 1998 revenues will be in the range of $1.4 million, a 50% increase over the same quarter last year. Further, we expect the results to yield a profit for the quarter. In 1997, Nutraceutix, Inc. established itself as an innovator in the development of proprietary nutritional products. In this formative year, the company secured an exclusive license for the use of the Calcium D-Glucarate patent for the prevention of lung, breast, prostate, liver and colon cancer. This compound was developed by researchers at M.D. Anderson Cancer Center. Nutraceutix then entered into a licensing agreement with Weider Nutrition for the retail sale of products containing Glucarate. Weider has extensive distribution of their Schiff[tm] and Great American Nutrition[tm] branded health supplement lines to health food stores and mass merchants. Although delayed several months for packaging design, Weider will begin shipping Schiff branded Glucarate products to health food stores in the latter part of March. NuStart Glucarate products will be shipped to mass merchants in April. In addition to manufacturing revenues, Nutraceutix will receive a royalty on Glucarate product sales. Beyond these retail channels, Nutraceutix has entered into discussions with several multi-level and direct marketing firms concerning the direct sales of Glucarate products. The company began installation of select pieces of high speed equipment in the first quarter of 1997, which was completed in the fourth quarter. Private label supplement manufacturing has been steadily growing since its installation. A second shift began in February to meet growing orders. Due to the extraordinary efforts of our Colorado staff, the company has met its goal as stated in our September 15, 1997 letter to shareholders of private label manufacturing of 50 products for 20 companies. These numbers do not include proprietary Glucarate products. Contributing to our private label business was the development of our shelf stable LIVEBACr tableting process for Lactobacillus health supplements. The company began manufacturing of the products using this technology for Schiff, Nature's Secret and other brands in the fourth quarter of 1997. The company continues to produce microbial products for agriculture. This business sector remains profitable. In 1998, Nutraceutix will continue its emphasis on proprietary product development. With Glucarate products soon to appear on retail shelves, Nutraceutix has begun assisting Weider with public relations, seminars and other educational projects focused on the health benefits of Glucarate. We expect Glucarate sales to parallel the gradual growth in consumer awareness as is typical of new products in the health supplement industry. In 1998, the company intends to become a fully reporting public company by the filing of a FORM 10-SB registration statement with the Securities Exchange Commission. We appreciate the continued support of our shareholders and wish you all a healthy new year. Sincerely, William D. St. John President